Intraoperative Intraperitoneal Chemoperfusion to treat Peritoneal Minimal Residual Disease in stage III Ovarian Cancer: a Randomized Phase II Trial Ghent University
Background: Stage III ovarian cancer (OC) remains an important cause of cancer related mortality in women. After successful initial treatment, most patients eventually develop recurrent peritoneal disease which can only arise from peritoneal minimal residual disease (pMRD) left after primary cytoreductive surgery (CRS). Intesification of locoregional therapy through intraoperative intraperitoneal chemoperfusion (IPC) immediately following CRS ...